Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
Japan’s JCR Pharmaceuticals has reached an agreement to acquire ArmaGen, a privately held US biopharmaceutical company, along with all its assets. 27 March 2020
Biotechnology
Sanofi Pasteur, the vaccines global business unit of French pharma major Sanofi (Euronext: SAN), and Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, will collaborate to develop a novel mRNA vaccine for COVID-19. 27 March 2020
Biotechnology
Oxford University biotech spinout Evox Therapeutics has entered into a rare disease-focused partnership with Japan’s largest drugmaker Takeda Pharmaceutical. 27 March 2020
Biotechnology
Bristol-Myers Squibb has received US approval for Zeposia (ozanimod) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. 26 March 2020
Biotechnology
The New England Journal of Medicine (NEJM) has published results from BELIEVE, the pivotal Phase III study evaluating the safety and efficacy of Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions. 26 March 2020
Biotechnology
US biotech Alector and Chinese company Innovent Biologics have signed a regional licensing agreement to develop and commercialize AL008 for oncology indications in China. 26 March 2020
Biotechnology
USA-based biotech Xencor has entered into a technology license agreement with Vir Biotechnology, in which Vir will have non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. 26 March 2020
Biotechnology
US biotech Gilead Sciences said on Wednesday that it has submitted a request to the US Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits that accompany the designation. 26 March 2020
Biotechnology
Ipsen shares began trading around 2% higher on Thursday morning, after the French biotech announced today it would restart the global Phase III MOVE trial, in people over the age of 14. 26 March 2020
Biotechnology
Sino-America immuno-oncology biotech firm BeiGene today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of Abraxane (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene, now a Bristol-Myers Squibb company. 25 March 2020
Biotechnology
Danish CNS specialist Lundbeck has published positive data from the Phase III PROMISE 2 trial in Neurology, the medical journal of the American Academy of Neurology. 25 March 2020
Biotechnology
US biotech Forge Therapeutics has entered into a research collaboration and option agreement with Swiss pharma giant Roche to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. 25 March 2020
Biotechnology
German biotechnology firm Sartorius has supported CanSino Biologics and Major General Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. 25 March 2020
Biotechnology
Ono Pharmaceutical has received manufacturing and marketing approval for Velexbru (tirabrutinib) tablet 80mg, a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of recurrent or refractory primary central nervous system lymphoma, in Japan. 25 March 2020
Biotechnology
Netherlands-based Norgine says it has acquired Azanta, a Denmark-based specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. 25 March 2020
Biotechnology
The Ghent, Belgium-based Flanders Interuniversity Institute for Biotechnology (VIB) is to conduct a trial, together with the University Hospital Ghent, to test Leukine (sargramostim) against respiratory illness caused by COVID-19. 25 March 2020
Biotechnology
UK novel RNA therapeutics specialist Silence Therapeutics saw its sales rocket 32% to 535.00 pence as markets opened today, as it announced a strategic collaboration with AstraZeneca to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for cardiovascular, renal, metabolic and respiratory diseases. 25 March 2020
Biotechnology
As the world watches aghast, the novel coronavirus continues to spread its tentacles around the globe, with cases of COVID-19 rising to nearly 375,000 on Tuesday, an increase of 75,000 from the day before. 25 March 2020
Biotechnology
Austro-American company CEL-SCI Corporation and the University of Georgia’s (UGA) Center for Vaccines and Immunology have announced a collaboration in COVID-19. 24 March 2020
Biotechnology
Stock in Novavax rose more than 15% by early afternoon on Tuesday, after the US vaccine developer announced positive data for a Phase III clinical trial of NanoFlu. 24 March 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze